KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 120 filers reported holding KEROS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $436,435 | +60.5% | 9,550 | +49.9% | 0.00% | 0.0% |
| Q1 2024 | $271,999 | +5.4% | 6,370 | -1.8% | 0.00% | 0.0% |
| Q4 2023 | $258,042 | +24.7% | 6,490 | 0.0% | 0.00% | – |
| Q3 2023 | $206,901 | -19.4% | 6,490 | +1.6% | 0.00% | -100.0% |
| Q2 2023 | $256,750 | -5.6% | 6,390 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $271,999 | -11.1% | 6,370 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $305,887 | -1.0% | 6,370 | -22.4% | 0.00% | 0.0% |
| Q3 2022 | $309,000 | +36.1% | 8,210 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $227,000 | -35.0% | 8,210 | +28.1% | 0.00% | 0.0% |
| Q1 2022 | $349,000 | -6.9% | 6,410 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $375,000 | +47.6% | 6,410 | 0.0% | 0.00% | – |
| Q3 2021 | $254,000 | -6.6% | 6,410 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $272,000 | +5.0% | 6,410 | +52.6% | 0.00% | 0.0% |
| Q1 2021 | $259,000 | -12.5% | 4,200 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $296,000 | – | 4,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 292,833 | $17,134,000 | 5.65% |
| Deep Track Capital, LP | 1,300,000 | $76,063,000 | 5.37% |
| Octagon Capital Advisors LP | 340,214 | $19,906,000 | 3.87% |
| Opaleye Management Inc. | 265,750 | $15,549,000 | 3.30% |
| First Light Asset Management, LLC | 552,098 | $32,303,000 | 2.31% |
| Altium Capital Management LP | 116,000 | $6,787,000 | 1.87% |
| Nantahala Capital Management | 796,698 | $46,615,000 | 1.64% |
| Orbimed Advisors | 1,679,417 | $98,263,000 | 1.26% |
| Darwin Global Management, Ltd. | 111,500 | $6,524,000 | 1.00% |
| Parkman Healthcare Partners LLC | 69,861 | $4,088,000 | 0.90% |